Deucravacitinib, an oral selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: efficacy and safety results of a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP)
In this medfyle
The scalp is involved in 80% of people with psoriasis, and can be burdensome and difficult to treat. Deucravacitinib is an oral TYK2 inhibitor approved for adults with moderate-to-severe plaque psoriasis – and with new data from PSORIATYK SCALP shared at EADV 2024.
About this Medfyle
©2024 Infomedica-Medfyle. All rights reserved.
Source: Deucravacitinib, an oral selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: efficacy and safety results of a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP). Callis-Duffin K, et al. Presented at EADV 2024; P3322; Abstract #5627.
The information and data provided is for information purposes only. The author(s) of the original original presentation had no involvement in the creation of this content.
